SCHEMBL10189704

SCHEMBL10189704

COc1cc(-c2nn[nH]c2-c2ccc(-c3cccnc3)cc2)cc(C)c1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
S1PR1 P21453 2/20 0.42
TLR8 Q9NR97 2/20 0.41
TLR7 Q9NYK1 2/20 0.41
PDGFRB P09619 3/20 0.41
PDGFRA P16234 2/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPY5R Q15761 1/20 0.41
CHEK1 O14757 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14619537 0.94 MAPK1 (0.45) MAPK1KDM4EHSD17B10POLBHTT
SCHEMBL10189738 0.94 MAPK1 (0.45) MAPK1KDM4EHSD17B10POLBHTT
SCHEMBL412804 0.87 MAPK1 (0.57) MAPK1KDM4EHSD17B10POLBHTT
SCHEMBL10189705 0.87 S1PR1 (0.38) S1PR1TLR8TLR7PDGFRBPDGFRA
SCHEMBL10189708 0.85 S1PR1 (0.37) HSD17B10S1PR1TLR8TLR7PDGFRB
SCHEMBL10189703 0.83 SMPD3 (0.41) KDM4EHSD17B10PDGFRBPDGFRALMNA
SCHEMBL10189737 0.82 CHEK1 (0.38) MAPK1POLBHTTCHEK1PIM1
SCHEMBL10189728 0.82 SMPD3 (0.41) MAPK1KDM4EHSD17B10PDGFRBLMNA
SCHEMBL10189699 0.82 ALDH1A1 (0.35) KDM4EPDGFRBPDGFRAPDE4AGSK3A
SCHEMBL10189709 0.81 CYP11B2 (0.37) KDM4ES1PR1PDGFRBPDGFRAGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9175022-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2015-11-03 US disclosed
US-8501790-B2 Compounds for the treatment of proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2013-08-06 US disclosed
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022118-A1 COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS RB1, MKI67, MAPRE1 MAPK1 750/4885KDM4E 2492/4885HSD17B10 2441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.